NYRADA INC (ASX:NYR) 12 Rüdiger Weseloh Ph.D. Non-Executive Director, joined the Board in June 2019 Rüdiger Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 19 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, Rüdiger spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen. Rüdiger also served 5 years on the Supervisory Board of Cytotools AG, Freiburg, Germany. Interest in shares and options 783,332 shares 600,000 unlisted options Special responsibilities N/A Directorship held in other listed entities (last 3 years) N/A Qualifications Rüdiger has a university diploma in Biochemistry from the University of Hannover and a PhD in Molecular Neurobiology, obtained at the Center for Molecular Neurobiology in Hamburg Ian Dixon Ph.D. Non-Executive Director, joined the Board in September 2020. Dr Dixon brings to the Board extensive entrepreneurial and technical experience in founding, building and running listed and unlisted technology-based companies. In 2011, Dr Dixon co-founded Cynata Inc, now a subsidiary of ASX-listed Cynata Therapeutics Ltd (ASX:CYP), a stem cell and regenerative medicine company progressing with its Cymerus stem cell therapy now progressing through Phase II studies. In 2014, Ian co-founded Cardio Therapeutics Pty Ltd and managed the PCSK9 cardiovascular discovery program until the company was acquired by Nyrada Inc in advance of the IPO of Nyrada in 2019. In 2018, the genetic medicines company founded by Ian listed as Exopharm Ltd (ASX:EX1) and Ian was a co-inventor of a number of inventions, including granted US patents, in the exosome field. Ian has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications. Interest in shares and options 10,380,699 shares 1,200,000 unlisted options Special responsibilities Member of Audit & Risk Committee Member of Remuneration & Nomination Committee Directorship held in other listed entities (last 3 years) Exopharm Limited (ASX:EX1) - resigned on 1 May 2024 Qualifications PhD in biomedical engineering, MBA and a Bachelor of Engineering
RkJQdWJsaXNoZXIy MjE2NDg3